يعرض 1 - 20 نتائج من 46 نتيجة بحث عن '"Highthroughput sequencing"', وقت الاستعلام: 0.58s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal
  3. 3
    Academic Journal

    المساهمون: Institute of Microbiology of the Czech Academy of Sciences Prague, Czech Republic (MBU / CAS), Czech Academy of Sciences Prague (CAS), Institute of Botany of the Czech Academy of Sciences (IB / CAS), Institute of Ecology and Earth Sciences Tartu, University of Tartu, Přírodovědecká fakulta, Univerzita Karlova Praha, Česká republika = Faculty of Sciences, Charles University Prague, Czech Republic (PřF UK), Univerzita Karlova Praha, Česká republika = Charles University Prague, Czech Republic (UK), Czech Science Foundation (21-17749S), ELIXIR CZ research infrastructure project (MEYS Grant no.LM2023055) through providing access to computing and storage facilities, European Regional Development Fund (Centre of Excellence EcolChange), Estonian Research Council (PRG1065 and PRG1789), institutional project RVO 67985939.

    المصدر: ISSN: 0028-646X.

  4. 4
    Academic Journal
  5. 5
    Academic Journal

    المساهمون: Institut Français de la Vigne et du Vin (IFV), Santé de la vigne et qualité du vin (SVQV), Université de Strasbourg (UNISTRA)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Comité Interprofessionnel du Vin de Champagne (CIVC)

    المصدر: ISSN: 0191-2917.

    Relation: info:eu-repo/semantics/altIdentifier/pmid/34420360; hal-03640833; https://hal.science/hal-03640833; https://hal.science/hal-03640833/document; https://hal.science/hal-03640833/file/islandora_150174.pdf; PUBMED: 34420360; WOS: 000763576400093

  6. 6
    Academic Journal

    المساهمون: Laboratoire Chrono-environnement (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté COMUE (UBFC)-Université Bourgogne Franche-Comté COMUE (UBFC), Faculté des Sciences et Technologies Université de Lorraine (FST ), Université de Lorraine (UL), Universität für Bodenkultur Wien = University of Natural Resources and Life Sciences Vienne, Autriche (BOKU)

    المصدر: ISSN: 1664-302X.

  7. 7
  8. 8
    Academic Journal
  9. 9
    Academic Journal

    المصدر: Russian Journal of Pediatric Hematology and Oncology; Том 6, № 2 (2019); 54-60 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 6, № 2 (2019); 54-60 ; 2413-5496 ; 2311-1267 ; 10.21682/2311-1267-2019-6-2

    وصف الملف: application/pdf

    Relation: https://journal.nodgo.org/jour/article/view/497/470; Schulte J.H., Schulte S., Heukamp L.C., Astrahantseff K., Stephan H., Fischer M., Schramm A., Eggert A. Targeted therapy for neuroblastoma: ALK inhibitors. Klin Padiatr 2013;225(6):303–8. doi:10.1055/s-0033-1357132.; Park J.R., Bagatell R., London W.B., Maris J.M., Cohn S.L., Mattay K.K., Hogarty M.; COG Neuroblastoma Committee. Children’s Oncology Group’s 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer 2013;60(6):985–93. doi:10.1002/pbc.24433.; Johnsen J.I., Dyberg C., Fransson S., Wickstrom M. Molecular mechanisms and therapeutic targets in neuroblastoma. Pharmacological Research 2018;131:164–76. doi:10.1016/j.phrs.2018.02.023.; Whittle S.B., Smith V., Doherty E., Zhao S., McCarty S., Zage P.E. Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther 2017;17(4):369–86. doi:10.1080/14737140.2017.1285230.; Mossé Y.P., Laudenslager M., Longo L., Cole K.A., Wood A., Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P., Laureys G., Speleman F., Kim C., Hou C., Hakonarson H., Torkamani A., Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M., Maris J.M. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455(7215):930–5. doi:10.1038/nature07261.; Chen Y., Takita J., Choi Y.L., Kato M., Ohira M., Sanada M., Wang L., Soda M., Kikuchi A., Igarashi T., Nakagawara A., Hayashi Y., Mano H., Ogawa S. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008;455(7215):971–4. doi:10.1038/nature07399.; George R.E., Sanda T., Hanna M., Fröhling S., Luther W. 2nd, Zhang J., Ahn Y., Zhou W., London W.B., McGrady P., Xue L., Zozulya S., Gregor V.E., Webb T.R., Gray N.S., Gilliland D.G., Diller L., Greulich H., Morris S.W., Meyerson M., Look A.T. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008;455(7215):975–8. doi:10.1038/nature07397.; Janoueix-Lerosey I., Lequin D., Brugieres L., Ribeiro A., de Pontual L., Combaret V., Raynal V., Puisieux A., Schleiermacher G., Pierron G., Valteau-Couanet D., Frebourg T., Michon J., Lyonnet S., Amiel J., Delattre O. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008;455(7215):967–70. doi:10.1038/nature07398.; Tolbert V.P., Coggins G.E., Maris J.M. Genetic susceptibility to neuroblastoma. Curr Opin Genet Dev 2017;42:81–90. doi:10.1016/j.gde.2017.03.008.; Catalogue of somatic mutations in cancer (GRCh38 COSMIC v.87). URL: https://cancer.sanger.ac.uk/cosmic/browse/tissue?hn=neuroblastoma&in=t&sn=autonomic_ganglia&ss=all; Padovan-Merhar O.M., Raman P., Ostrovnaya I., Kalletla K., Rubnitz K.R., Sanford E.M., Ali S.M., Miller V.A., Mossé Y.P., Granger M.P., Weiss B., Maris J.M., Modak S. Enrichment of targetable mutations in the relapsed neuroblastoma genome. PLоS Genetics 2016;12(12):e1006501. doi:10.1371/journal.pgen.1006501.; Trigg R.M., Turner S.D. ALK in neuroblastoma: biological and therapeutic implications. Cancers (Basel) 2018;10(4):113. doi:10.3390/cancers10040113.; Buechner J., Tømte E., Haug B.H., Henriksen J.R., Løkke C., Flægstad T., Einvik C. Tumour-suppressor microRNAs let-7 and mir101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Br J Cancer 2011;105(2):296-303. doi:10.1038/bjc.2011.220.; Hallberg B., Palmer R.H. The role of the ALK receptor in cancer biology. Ann Oncol 2016;27(Suppl 3):iii4–iii15. doi:10.1093/annonc/mdw301.; Eleveld T.F., Oldridge D.A., Bernard V., Koster J., Colmet Daage L., Diskin S.J., Schild L., Bentahar N.B., Bellini A., Chicard M., Lapouble E., Combaret V., Legoix-Né P., Michon J., Pugh T.J., Hart L.S., Rader J., Attiyeh E.F., Wei J.S., Zhang S., Naranjo A., Gastier-Foster J.M., Hogarty M.D., Asgharzadeh S., Smith M.A., Guidry Auvil J.M., Watkins T.B., Zwijnenburg D.A., Ebus M.E., van Sluis P., Hakkert A., van Wezel E., van der Schoot C.E., Westerhout E.M., Schulte J.H., Tytgat G.A., Dolman M.E., Janoueix-Lerosey I., Gerhard D.S., Caron H.N., Delattre O., Khan J., Versteeg R., Schleiermacher G., Molenaar J.J., Maris J.M. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet 2015;47(8):864–71. doi:10.1038/ng.3333.; Bresler S.C., Weiser D.A., Huwe P.J., Park J.H., Krytska K., Ryles H., Laudenslager M., Rappaport E.F., Wood A.C., McGrady P.W., Hogarty M.D., London W.B., Radhakrishnan R., Lemmon M.A., Mossé Y.P. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell 2014;26(5):682–94. doi:10.1016/j.ccell.2014.09.019.; Passoni L., Longo L., Collini P., Coluccia A.M., Bozzi F., Podda M., Gregorio A., Gambini C., Garaventa A., Pistoia V., Del Grosso F., Tonini G.P., Cheng M., Gambacorti-Passerini C., Anichini A., Fossati-Bellani F., Di Nicola M., Luksch R. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res 2009;69(18):7338–46. doi:10.1158/0008-5472.CAN-08-4419.; Schulte J.H., Bachmann H.S., Brockmeyer B., Depreter K., Oberthür A., Ackermann S., Kahlert Y., Pajtler K., Theissen J., Westermann F., Vandesompele J., Speleman F., Berthold F., Eggert A., Brors B., Hero B., Schramm A., Fischer M. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. Clin Cancer Res 2011;17(15):5082–92. doi:10.1158/1078-0432.CCR-10-2809.; Ogura T., Hiyama E., Kamei N., Kamimatsuse A., Ueda Y., Ogura K. Clinical feature of anaplastic lymphoma kinase-mutated neuroblastoma. J Pediatr Surg 2012;47(10),1789–96. doi:10.1016/j.jpedsurg.2012.05.007.; Mosse Y.P., Lim M.S., Voss S.D., Wilner K., Ruffner K., Laliberte J., Rolland D., Balis F.M., Maris J.M., Weigel B.J., Ingle A.M., Ahern C., Adamson P.C., Blaney S.M. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncol 2013;14(6):472–80. Обзоры лит ерат уры %7C%7C Li terature revi ews doi:10.1016/S1470-2045(13)70095-0.; Bellini A., Bernard V., Leroy Q., Rio Frio T., Pierron G., Combaret V., Lapouble E., Clement N., Rubie H., Thebaud E., Chastagner P., Defachelles A.S., Bergeron C., Buchbinder N., Taque S., Auvrignon A., Valteau-Couanet D., Michon J., Janoueix-Lerosey I., Delattre O., Schleiermacher G. Deep sequencing reveals occurrence of subclonal ALK mutations in neuroblastoma at diagnosis. Clin Cancer Res 2015;21(21):4913–21. doi:10.1158/1078-0432.CCR-15-0423.; De Brouwer S., De Preter K., Kumps C., Zabrocki P., Porcu M., Westerhout E.M., Lakeman A., Vandesompele J., Hoebeeck J., Van Maerken T., De Paepe A., Laureys G., Schulte J.H., Schramm A., Van Den Broecke C., Vermeulen J., Van Roy N., Beiske K., Renard M., Noguera R., Delattre O., Janoueix-Lerosey I., Kogner P., Martinsson T., Nakagawara A., Ohira M., Caron H., Eggert A., Cools J., Versteeg R., Speleman F. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 2011;16(17): 4353-62. doi:10.1158/1078-0432.CCR-09-2660.; Berry T., Luther W., Bhatnagar N., Jamin Y., Poon E., Sanda T., Pei D., Sharma B., Vetharoy W.R., Hallsworth A., Ahmad Z., Barker K., Moreau L., Webber H., Wang W., Liu Q., Perez-Atayde A., Rodig S., Cheung N.K., Raynaud F., Hallberg B., Robinson S.P., Gray N.S., Pearson A.D., Eccles S.A., Chesler L., George R.E. The ALK (F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell 2012;22(1):117–30. doi:10.1016/j.ccr.2012.06.001.; Lopez-Delisle L., Pierre-Eugene C., Louis-Brennetot C., Surdez D., Raynal V., Baulande S., Boeva V., Grossetête-Lalami S., Combaret V., Peuchmaur M., Delattre O., Janoueix-Lerosey I. Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis. Oncogene 2018;37(11):1417–29. doi:10.1038/s41388-017-0039-5.; Matthay K.K., George R.E., Yu A.L. Promising therapeutic targets in neuroblastoma. Clin Cancer Res 2012;18(10):2740–53. doi:10.1158/1078-0432.CCR-11-1939.; Carpenter E.L., Mossé Y.P. Targeting ALK in neuroblastoma – preclinical and clinical advancement. Nat Rev Clin Oncol 2012;9(7):391–9. doi:10.1038/nrclinonc.2012.72.; Rodig S.J., Shapiro G.I. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Investig Drugs 2010;11(12):1477–90. PMID: 21154129.; Felkali L., Banusz R., Kovalszky I., Sápi Z., Garami M., Papp G., Karászi K., Varga E., Csóka M. The presence of ALK alterations and clinical relevance of crizotinib treatment in pediatric solid tumors. Pathol Oncol Res 2019;25(1):217–24. doi:10.1007/s12253-017-0332-1.; Azarova A.M., Gautam G., George R.E. Emerging importance of ALK in neuroblastoma. Semin Cancer Biol 2011;21(4):267–75. doi:10.1016/j.semcancer.2011.09.005.; Bresler S.C., Wood A.C., Haglund E.A., Courtright J., Belcastro L.T., Plegaria J.S., Cole K., Toporovskaya Y., Zhao H., Carpenter E.L., Christensen J.G., Maris J.M., Lemmon M.A., Mosse Y.P. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med 2011;3(108):108ra114. doi:10.1126/scitranslmed.3002950.; Infarinato N.R., Park J.H., Krytska K., Ryles H.T., Sano R., Szigety K.M., Li Y., Zou H.Y., Lee N.V., Smeal T., Lemmon M.A., Mossé Y.P. The ALK/ROS1 inhibitor PF-06463922 overcomes primary resistance to crizotinib in ALK-driven neuroblastoma. Cancer Discov 2016;6(1):96–107. doi:10.1158/2159-8290.CD-15-1056.; Friboulet L., Li N., Katayama R., Lee C.C., Gainor J.F., Crystal A.S., Michellys P.Y., Awad M.M., Yanagitani N., Kim S., Pferdekamper A.C., Li J., Kasibhatla S., Sun F., Sun X., Hua S., McNamara P., Mahmood S., Lockerman E.L., Fujita N., Nishio M., Harris J.L., Shaw A.T., Engelman J.A. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014;4(6):662–73. doi:10.1158/2159-8290.CD-13-0846.; Clinicaltrials.gov. URL: https://clinicaltrials.gov/ct2/results?term=neuroblastoma+alk&age_v=&age=0&gndr=&type=&rslt=&Search=Apply; Krytska K., Ryles H.T., Sano R., Raman P., Infarinato N.R., Hansel T.D., Makena M.R., Song M.M., Reynolds C.P., Mossé Y.P. Crizotinib synergizes with chemotherapy in preclinical models of neuroblastoma. Clin Cancer Res 2016;22(4):948–60. doi:10.1158/1078-0432.CCR-15-0379.; Zhang L., Wu B., Baruchel S. Oral metronomic topotecan sensitizes crizotinib antitumor activity in ALKF1174L drug-resistant neuroblastoma preclinical models. Transl Oncol 2017;10(4):604–11. doi:10.1016/j.tranon.2017.04.008.; A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL). [Электронный ресурс]: http://ClinicalTrials.gov. Identifier: NCT03126916.; https://journal.nodgo.org/jour/article/view/497

  10. 10
    Academic Journal
  11. 11

    المؤلفون: Michel Chalot, Markus Puschenreiter

    المساهمون: Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Faculté des Sciences et Technologies [Université de Lorraine] (FST ), Université de Lorraine (UL), University of Natural Resources and Life Sciences (BOKU)

    المصدر: Frontiers in Microbiology
    Frontiers in Microbiology, Frontiers Media, 2021, 12, ⟨10.3389/fmicb.2021.763566⟩
    Frontiers in Microbiology, Vol 12 (2021)

  12. 12
    Academic Journal
  13. 13
    Dissertation/ Thesis
  14. 14

    المساهمون: Curci, Pasquale L., Bergès, Hélène, Marande, William, Maccaferri, Marco, Tuberosa, Roberto, Sonnante, Gabriella, Institute of Biosciences and Bioresources, Consiglio Nazionale delle Ricerche [Roma] (CNR), Centre National de Ressources Génomiques Végétales (CNRGV), Institut National de la Recherche Agronomique (INRA), Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO), Italian Ministry MIUR project: 'Sviluppo tecnologico e innovazione per la sostenibilita e competitivita della cerealicoltura meridionale' [PON01_01145 ISCOCEM ], Italian Ministry MIUR project: PRIN 'Identificazione e caratterizzazione di geni utili ad incrementare la produttivita e sostenibilita del frumento duro' [2010Z77XAX_004]

    المصدر: Euphytica
    Euphytica, 2018, 214 (2), 13 p. ⟨10.1007/s10681-017-2105-z⟩
    Euphytica (Wagening.) (2018). doi:10.1007/s10681-017-2105-z
    info:cnr-pdr/source/autori:Pasquale L. Curci, Hélène Bergès, William Marande, Marco Maccaferri, Roberto Tuberosa, Gabriella Sonnante/titolo:Asparagine synthetase genes (AsnS1 and AsnS2) in durum wheat: structural analysis and expression under nitrogen stress/doi:10.1007%2Fs10681-017-2105-z/rivista:Euphytica (Wagening.)/anno:2018/pagina_da:/pagina_a:/intervallo_pagine:/volume
    Europe PubMed Central

    وصف الملف: ELETTRONICO

  15. 15

    المساهمون: Department of Bio-engineering Sciences, Industrial Microbiology, Flanders Research Consortium on Fermented Foods and Beverages, Belgian-Argentinean Research Consortium on Fermented Foods and Beverages, Faculty of Sciences and Bioengineering Sciences

    المصدر: Applied and environmental microbiology. 83(1)

  16. 16
    Academic Journal
  17. 17
  18. 18
    Dissertation/ Thesis
  19. 19
    Dissertation/ Thesis
  20. 20
    Dissertation/ Thesis